WCG
BCLI
Weaver Consulting Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $17.5K | Hold |
15,623
| – | – | ﹤0.01% | 246 |
|
|
2025
Q1 | $19.7K | Hold |
15,623
| – | – | 0.01% | 222 |
|
|
2024
Q4 | $35.5K | Sell |
15,623
-1
| -0% | -$2 | 0.01% | 219 |
|
|
2024
Q3 | $54K | Hold |
15,624
| – | – | 0.02% | 220 |
|
|
2024
Q2 | $79.3K | Buy |
15,624
+2,334
| +18% | +$11.9K | 0.03% | 201 |
|
|
2024
Q1 | $113K | Hold |
13,290
| – | – | 0.04% | 197 |
|
|
2023
Q4 | $54.4K | Buy |
13,290
+6,666
| +101% | +$27.3K | 0.02% | 192 |
|
|
2023
Q3 | $19.9K | Buy |
6,624
+2,310
| +54% | +$6.93K | 0.01% | 184 |
|
|
2023
Q2 | $133K | Buy |
4,314
+66
| +2% | +$2.04K | 0.06% | 180 |
|
|
2023
Q1 | $210K | Sell |
4,248
-148
| -3% | -$7.33K | 0.1% | 170 |
|
|
2022
Q4 | $108K | Sell |
4,396
-1,869
| -30% | -$46K | 0.06% | 173 |
|
|
2022
Q3 | $415K | Sell |
6,265
-712
| -10% | -$47.2K | 0.24% | 85 |
|
|
2022
Q2 | $289K | Sell |
6,977
-1,690
| -19% | -$70K | 0.16% | 126 |
|
|
2022
Q1 | $437K | Sell |
8,667
-1,700
| -16% | -$85.7K | 0.21% | 89 |
|
|
2021
Q4 | $622K | Buy |
10,367
+6,934
| +202% | +$416K | 0.3% | 59 |
|
|
2021
Q3 | $170K | Buy |
3,433
+174
| +5% | +$8.62K | 0.09% | 146 |
|
|
2021
Q2 | $186K | Sell |
3,259
-74
| -2% | -$4.22K | 0.1% | 143 |
|
|
2021
Q1 | $192K | Buy |
+3,333
| New | +$192K | 0.12% | 136 |
|